Archives

01 Jun

Attraction of young people toward science – strategic wish of the knowledge society – 21-22 June 2018, Bucharest, Romania

[Source: Research & Innovation] The purpose of the workshop will be a good reason for the dissemination and promotion of

01 Jun

Tattoos in the biotech industry

What is the general opinion on tattoos in biotech companies? I’m sure it depends on the company, but I am

01 Jun

Addressing Food Innovation Across the Value Chain at Convention

In a matter of days countless biotechnology companies will descend on Boston for the 2018 BIO International Convention. We’ve highlighted

01 Jun

Arcturus Reinstates Fired CEO After Regime Change in Boardroom

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT) on Thursday reinstated fired CEO Joseph Payne and named ResMed

31 May

Exact Sciences Needs New Study to Fully Benefit From ACS Change

Exact Sciences has already set plans in place to try to benefit from new guidelines from the American Cancer Society,

31 May

Research Headlines – Flagship ecosystems… serve nature ‘and’ people

[Source: Research & Innovation] Environmental imperatives aside, healthy ecosystems and rich biodiversity are essential to human populations too! This is

31 May

Informa Agribusiness: Systematic Change Needed for U.S., China and the World to Benefit from Biotech Innovation

In 2017, U.S. farmers exported nearly $20 billion worth of agricultural products to China, and nearly two-thirds of those products

31 May

Biotechnology Reagents Market Analysis and Research Report by Experts 2018 to 2025

The Report entitled Biotechnology Reagents Market 2018 analyses the important factors of the Biotechnology Reagents market based on present …

31 May

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

A Vertex Pharmaceuticals partnership with CRISPR Therapeutics to test a genetically engineered drug in patients as a treatment for sickle

30 May

Settlement Ends Fight at Arcturus Therapeutics; New Board Named

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT) named four new board members Tuesday, after the four directors